Biocon signs agreement with US firma
The pact is for exclusive commercialisation rights for a novel therapy for the treatment of sepsis.
New Delhi, September 14, 2013: The Indian biotechnology firm Biocon has inked a pact with the US based CytoSorbents Corporation, under which the Bengaluru-based firm will have the exclusive commercialisation rights for CytoSorb, a novel therapy for the treatment of sepsis, in India and some emerging markets. The Indian company said in a statement that it has entered into this strategic partnership for India and select emerging markets under which Biocon will have the exclusive commercialisation rights for CytoSorb.
It is expected that this partnership with CytoSorbents will help the company to address the huge unmet need of sepsis management in India and emerging markets. The company also said that this move shows the commitment of the company to bring differentiated products to the Indian market.
"Biocon's network will enable rapid access, education, training, and support of physicians in the largest hospitals throughout India and other emerging markets," said Chris Cramer, Vice President (Business Development), CytoSorbents.